Compremium

What Compremium does

Compremium AG is a privately held Swiss medical device company founded in 2020 and headquartered in Muri b. Bern, Switzerland. The company develops non-invasive diagnostic systems that quantify soft tissue compressibility and central venous pressure (CVP), serving orthopedic trauma, emergency medicine, pediatric, and critical care settings in hospitals. Its flagship product, the Compremium Quantis ST (formerly CPMX1), received FDA 510(k) clearance in April 2023 and CE Marking in December 2025, enabling commercial sales in U.S. and European markets. Named institutional users and partners include Children's National Hospital, Inselspital (Bern University Hospital), Charité Berlin, Schulthess Klinik, Universitätsklinikum Freiburg, Maxima Medisch Center, Hennepin Healthcare, and NASA.

Compremium's platform technology combines ultrasound imaging with proprietary pressure sensing to compute a quantitative CP Value, defined as the percent change in compartment thickness between low and high applied pressures. The architecture supports a portfolio of indications: the Quantis ST targets orthopedic trauma (acute compartment syndrome diagnosis and surgical timing), while the Quantis CVP system, which received FDA Breakthrough Device Designation in January 2026, extends the platform to non-invasive central venous pressure measurement with reported r=0.95 correlation to the gold-standard invasive measurement. Validation is supported by 40+ clinical studies across multiple indications and eight years of continuous use aboard the International Space Station under a NASA collaboration that includes a commitment of CPMX1 for deep-space missions to the Moon and Mars.

Commercially, Compremium operates a direct enterprise sales model targeting U.S. and European hospitals, with a VP of Sales building the U.S. commercial organization from the ground up and distribution coverage extending into the DACH region. Revenue is generated through hardware sales of the Quantis ST probe and system with associated software, priced quote-based under multi-year contract structures typical of enterprise medical capital equipment; a potential software/services layer is referenced but not yet a material revenue stream. The company is privately funded by founders and private investors; the only disclosed external funding event is a $50,000 pediatric device innovation grant awarded in October 2024, and no institutional venture or growth equity investors are named in available sources.

Name

Compremium

Legal name

Compremium AG

Website

https://compremium.ch

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Compremium AG is a Swiss medical device company that develops non-invasive diagnostic systems combining ultrasound imaging with pressure sensing to quantify soft tissue compressibility and central venous pressure for hospitals, trauma centers, and clinical researchers.

Ownership category

akta.pro rank

Product category

Medical Devices / Diagnostic Imaging Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

Keywords

• Non-invasive diagnostics
• Compartment syndrome monitoring
• Soft tissue assessment
• Central venous pressure
• Medical imaging devices

Headquarters

HQ city

Muri

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Sale of Quantis ST hardware system and associated software for non-invasive soft tissue compressibility measurement. FDA-cleared and CE-marked product currently commercialized in U.S. and EU markets.
2. Software/Services: Quantis ST Software provides real-time measurement outputs and structured data for clinical reporting. Potential subscription or service model for software updates and support.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Compremium designs, manufactures, and sells non-invasive medical devices that combine ultrasound imaging with pressure sensing to quantify soft tissue compressibility and central venous pressure. Its flagship Compremium Quantis ST (formerly CPMX1) is an FDA-cleared and CE-marked system used by orthopedic trauma and emergency medicine teams to support clinical decisions from triage to discharge. The company also offers Compremium Quantis CVP, a non-invasive central venous pressure measurement system with FDA Breakthrough Device Designation, sold to hospitals, trauma centers, academic medical centers, and health systems.

Product overview

Compremium offers a platform-based product portfolio centered on non-invasive pressure measurement technology. The core offering consists of two main products: Compremium Quantis ST (formerly CPMX1) for soft tissue compressibility assessment, and Compremium Quantis CVP for central venous pressure measurement. Quantis ST is FDA-cleared and CE-marked, while Quantis CVP has received FDA Breakthrough Device Designation and is for investigational use only. Both products integrate hardware (Probe) and software components and are based on proprietary technology combining ultrasound imaging with pressure sensing. The platform targets orthopedic trauma, emergency medicine, sports medicine, and critical care applications.

Differentiator

Problem solved

Functional benefit

Brands

• Quantis ST: Non-invasive medical device for quantifying soft tissue compressibility. FDA-cleared and CE-marked solution for ortho trauma care, providing objective measurement of muscle compartment compressibility.
• Quantis CVP

Products and services

• Compremium Quantis ST A non-invasive medical device that quantifies soft tissue compressibility for objective assessment in orthopedic trauma care. It measures relative compartment compressibility and provides CP Values in real time to support clinical decision-making from triage to discharge. FDA-cleared (April 2023) and CE-marked (December 2025). Sold to hospitals, trauma centers, academic medical centers, and health systems.
• Compremium Quantis CVP A next-generation non-invasive solution for directly measuring central venous pressure (CVP) built on Compremium's ultrasound-and-pressure-sensing platform with AI-enhanced usability. Correlation of r=0.95 to gold standard. Currently for investigational use only. Received FDA Breakthrough Device Designation in January 2026.

Quantifiable outcome

• Interclass Correlation Coefficient (ICC) of 0.911 achieved in reliability study with p<0.001
• +5 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered secondary and core.

• Universitätsklinikum FreiburgsecondaryStrategic or Co-development Partner · 1 March 2025Kickoff of collaboration in March 2025. Expansion of European clinical research network.
• Children's National HospitalcoreStrategic or Co-development Partner · 11 February 2025Strategic partnership making Children's National the Pediatric Innovation Hub for Compremium. Joint clinical studies, research projects, and commercialization focused on non-invasive pressure monitoring for pediatric patients. Initial focus on congenital heart disease patients requiring non-invasive central venous pressure monitoring.
• Charité - Universitätsmedizin BerlincoreStrategic or Co-development Partner · 1 March 2023Clinical partnership established with Prof. Dr. med. Ulrich Stöckle, Executive Director, Center for Musculoskeletal Surgery. Clinical validation and KOL engagement for Quantis ST technology.
• Inselspital (Bern University Hospital)coreStrategic or Co-development Partner · 1 November 2022FDA clearance study conducted at University Hospital Inselspital Bern by Dr. med. Beat Lehmann. First-in-human clinical study for thyroid cancer diagnostic device. Scientific collaboration with Prof. Dr. med. Annalisa Berzigotti for hepatology research. Kickoff of collaboration for Quantis CVP development.
• Schulthess Klinik (Zurich)secondaryStrategic or Co-development Partner · 1 May 2022Andrea Rytz, CEO of Schulthess Klinik in Zurich initiated scientific collaboration with Compremium in May 2022.
• Maxima Medisch Center (Netherlands)secondaryStrategic or Co-development Partner · 1 January 2021Scientific collaboration started with Dr. med. Marc Scheltinga in Veldhoven, Netherlands. Clinical validation research.
• NASA (Johnson Space Center)coreStrategic or Co-development Partner · 1 January 2013Long-term partnership for human advancement research. NASA committed CPMX1 System for deep space missions to Moon and Mars. Device in use on International Space Station since 2018. Collaborative research on fluid shifts and cardiovascular effects of spaceflight.
• ETH ZurichcoreTechnology or Integration · 1 January 2013VeinPress prototype further developed in collaboration with ETH Zurich. Scientific partner in winning Swiss Medtech Award 2014. Initial technology development partnership.
• University Hospital BaselcoreTechnology or Integration · 1 January 2013Early scientific collaboration and feasibility testing. Scientific partner in Swiss Medtech Award 2014. First scientific results published with university hospital researchers.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Edwards Lifesciences: Global leader in hemodynamic monitoring, including central venous pressure measurement and invasive/non-invasive pressure technologies. Most directly comparable to Compremium's Quantis CVP product given overlapping CVP/hemodynamic monitoring use case in ICU and surgical settings.
• Masimo: Pioneer in non-invasive patient monitoring (SET pulse oximetry, rainbow parameters). Comparable to Compremium as a non-invasive monitoring platform company that uses proprietary sensor and signal-processing technology to displace invasive measurement standards.
• Nonin Medical: Specialist in non-invasive medical monitoring devices including pulse oximetry and capnography. Comparable to Compremium as a focused non-invasive monitoring company bringing objective, sensor-based measurements into clinical practice.

Broad incumbents

• ICU Medical: Manufacturer of hemodynamic monitoring systems, IV therapy products, and critical care devices including CVP measurement solutions. Comparable to Compremium's CVP product line and broader ICU monitoring ambitions.
• Stryker: Major orthopedic trauma and surgical device company serving the same hospital orthopedic surgery departments as Compremium's primary Quantis ST customer base. Comparable as a competitor for hospital budgets in orthopedic trauma care.
• GE HealthCare: Global ultrasound and patient monitoring manufacturer. Compremium's ultrasound-plus-pressure-sensing platform intersects with GE's ultrasound franchise, and GE's patient monitoring portfolio overlaps with the CVP/hemodynamic monitoring opportunity.
• Philips Healthcare: Provides patient monitoring and clinical decision support solutions used in ICUs and emergency departments. Comparable as a broad incumbent competing for the same hospital monitoring budgets and value analysis committee approvals.
• Mindray: Global manufacturer of patient monitoring, ultrasound, and in-vitro diagnostic equipment with growing share in U.S. and European hospitals. Comparable as a multi-modality monitoring competitor for hospital procurement budgets.
• Zimmer Biomet: Global orthopedic medical device leader with deep relationships in trauma surgery, sports medicine, and surgical timing decisions. Comparable as a competitor and potential partner for Compremium's orthopedic trauma use case.

Emerging players

• Penumbra: Vascular and neurovascular medical device company with growing peripheral franchise and focus on minimally invasive therapies. Comparable as an innovative specialty medtech pursuing adjacent vascular/hemodynamic clinical applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/compremium-ag

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Compremium